The EMA has validated Atara Biotherapeutics' Marketing Authorization Application (MAA) for tabelecleucel (tab-cel), the first time an off-the-shelf allogeneic T-cell therapy will be evaluated by any regulatory agency in the world.
French biotech raises €5m, looks to restore patient response to anticancer immunotherapies
Pipelines
Speed, flexibility and innovation: Rethinking the way biopharma industry operates
COVID-19
Development of Omicron-specific vaccines is under way
COVID-19
Ncardia secures $60m to expand iPSC platform
Cell & Gene Therapies
